Systemic therapeutic efficacy is central to determining the outcome of patients with
metastatic colorectal cancer (CRC). In these patients, there is a critical need for predictive …

The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Advances in the treatment of metastatic colorectal cancer have led to an improvement in
survival from 12 months with fluorouracil monotherapy to approximately 2 years. This is …

Although significant progress has been made in colorectal cancer (CRC) treatment within
the last decade with the approval of multiple new agents, the prognosis for patients with …

Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge,
which is further complicated by the common occurrence of several molecular alterations that …

Introduction: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers
with an increasing incidence in the younger patient population. Until the last decade, limited …

Over the past 20 years, substantial advances have been made in the treatment of patients
with metastatic colorectal cancer (mCRC). In particular, there is now a wide range of options …

The 5-year survival probability for patients with metastatic colorectal cancer has not
drastically changed over the last several years, nor has the backbone chemotherapy in first …

Tumour metastasis is the major cause of morbidity and mortality from colorectal cancer.
While improvements in quality of life and patient survival have been made over the past 10 …